# Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

> **NCT00287820** · PHASE4 · COMPLETED · sponsor: **Nathan Kline Institute for Psychiatric Research** · enrollment: 46 (estimated)

## Conditions studied

- Schizophrenia
- Diabetes
- Metabolic Syndrome
- Hyperglycemia

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** olanzapine
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00287820
- **Lead sponsor:** Nathan Kline Institute for Psychiatric Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2011-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287820, "Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00287820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*